Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 225 7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

LabPsycho May. 10 at 2:28 PM

$CNTX Saw the writing on the wall several months ago. Below predicted Events 1 and 2 realized and in order. Will there be Event 3 - a dilution or worse private placement with warrants? And will it be before or after any data update? IMO, before = bad, after = good.

1 · Reply

SpencerF May. 7 at 1:52 PM

$CNTX best to dump and buy after dilution? Or could it run at any time?

1 · Reply

elmono May. 6 at 3:16 PM

$CNTX thrash co…🤷‍♂️. Only down, no run into data. No market conviction

0 · Reply

hugoraciel May. 5 at 9:11 PM

$CNTX this is MM fkn around w prices

0 · Reply

BigDaddyCapital May. 4 at 8:41 PM

$CNTX preparing for offering post data. Would be great move by management

0 · Reply

VA_24 May. 4 at 1:54 PM

$CNTX Looks like they are getting ready to dilute 🤦‍♂️ They’re asking to increase shares by 100mill to 300 million Why? The float is 90+ and the shares are 200 million

1 · Reply

StockConsultant Apr. 29 at 12:26 AM

$CNTX Context Therapeutics stock, nice day off the triple support area at https://stockconsultant.com/?CNTX

0 · Reply

elmono Apr. 24 at 11:29 PM

$CNTX nearing the point of dumping position…chart looks very weak

1 · Reply

hugoraciel Apr. 20 at 10:07 PM

$ARDX $GME $GNS $CNTX $AMC

1 · Reply

elmono Apr. 20 at 8:00 PM

$CNTX very weak for over a month now in a strong biotech trend….. something seems not right? Cash problem?

0 · Reply

Context Therapeutics reports Q1 EPS (9c), consensus (12c)

May 6, 2026, 4:18 PM EDT - 7 days ago

Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

2026-04-02T11:54:29.000Z - 5 weeks ago

Context Therapeutics granted Fast Track Designation to CTIM-76 by FDA

Apr 2, 2026, 7:30 AM EDT - 5 weeks ago

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

2026-03-24T10:35:12.000Z - 7 weeks ago

Context Therapeutics price target raised to $7 from $4 at Piper Sandler

Mar 23, 2026, 4:16 PM EDT - 7 weeks ago

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 11, 2026, 9:20 AM EDT - 2 months ago

Context Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 10:30 AM EST - 2 months ago

Context Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 9, 2026, 7:30 AM EST - 3 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Jan 16, 2026, 4:05 PM EST - 4 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-12-22T12:16:26.000Z - 5 months ago

Context Therapeutics initiated with a Buy at JonesResearch

Nov 10, 2025, 3:00 PM EST - 6 months ago

Context Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T12:35:45.000Z - 6 months ago

Context Therapeutics highlights CT-95, CT-202 programs at SITC meeting

Nov 7, 2025, 7:30 AM EST - 6 months ago

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

2025-11-06T11:11:21.000Z - 6 months ago

Context Therapeutics price target raised to $5 from $4 at H.C. Wainwright

2025-11-05T23:00:43.000Z - 6 months ago

Context Therapeutics reports Q3 EPS (10c), consensus (9c)

Nov 5, 2025, 4:15 PM EST - 6 months ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Oct 6, 2025, 7:30 AM EDT - 7 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 3, 2025, 4:15 PM EDT - 7 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2025-10-02T10:45:36.000Z - 7 months ago

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-10-02T10:05:17.000Z - 7 months ago

Context Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-09-29T14:10:09.000Z - 8 months ago

Context Therapeutics management to meet with Maxim

2025-09-17T20:40:12.000Z - 8 months ago

Context Therapeutics initiated with a Buy at Guggenheim

2025-09-17T20:21:12.000Z - 8 months ago

Context Therapeutics initiated with a Buy at Guggenheim

2025-09-10T15:35:13.000Z - 8 months ago

Context Therapeutics management to meet with Maxim

2025-08-07T10:05:38.000Z - 9 months ago

Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright

2025-08-06T21:55:25.000Z - 9 months ago

Context Therapeutics reports Q2 EPS (9c), consensus (5c)

Aug 6, 2025, 4:11 PM EDT - 10 months ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

2025-06-26T10:50:35.000Z - 11 months ago

Context Therapeutics price target lowered to $4 from $4.50 at Piper Sandler

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

2025-05-29T11:36:01.000Z - 1 year ago

Context Therapeutics appoints Chagin as Chief Medical Officer

May 29, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 7, 2025, 4:09 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

2025-05-05T21:25:15.000Z - 1 year ago

Context Therapeutics CMO Claudio Dansky Ullmann to depart

May 5, 2025, 4:05 PM EDT - 1 year ago

Context Therapeutics Announces Chief Medical Officer Transition

2025-04-30T11:38:36.000Z - 1 year ago

Context Therapeutics presents preclinical data on CT-95

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Mar 26, 2025, 4:02 PM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 1 year ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Jan 14, 2025, 4:58 PM EST - 1 year ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 1 year ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 19, 2024, 1:50 PM EST - 1 year ago

Context Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 2:45 PM EST - 1 year ago

Context Therapeutics Transcript: UBS Global Healthcare Conference

Nov 11, 2024, 3:00 PM EST - 1 year ago

Context Therapeutics Transcript: Guggenheim Inaugural Global Healthcare Conference

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 2:00 PM EDT - 1 year ago

Context Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 8, 2024, 4:06 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 2, 2024, 7:31 AM EDT - 2 years ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 7:43 AM EDT - 2 years ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 3 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 3 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Apr 18, 2023, 10:15 AM EDT - 3 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 22, 2023, 5:08 PM EDT - 3 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 15, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 4, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Dec 8, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Nov 29, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 21, 2022, 9:11 AM EST - 3 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 9, 2022, 4:14 PM EST - 3 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

LabPsycho May. 10 at 2:28 PM

1 · Reply

SpencerF May. 7 at 1:52 PM

$CNTX best to dump and buy after dilution? Or could it run at any time?

1 · Reply

elmono May. 6 at 3:16 PM

$CNTX thrash co…🤷‍♂️. Only down, no run into data. No market conviction

0 · Reply

hugoraciel May. 5 at 9:11 PM

$CNTX this is MM fkn around w prices

0 · Reply

BigDaddyCapital May. 4 at 8:41 PM

$CNTX preparing for offering post data. Would be great move by management

0 · Reply

VA_24 May. 4 at 1:54 PM

$CNTX Looks like they are getting ready to dilute 🤦‍♂️ They’re asking to increase shares by 100mill to 300 million Why? The float is 90+ and the shares are 200 million

1 · Reply

StockConsultant Apr. 29 at 12:26 AM

$CNTX Context Therapeutics stock, nice day off the triple support area at https://stockconsultant.com/?CNTX

0 · Reply

elmono Apr. 24 at 11:29 PM

$CNTX nearing the point of dumping position…chart looks very weak

1 · Reply

hugoraciel Apr. 20 at 10:07 PM

$ARDX $GME $GNS $CNTX $AMC

1 · Reply

elmono Apr. 20 at 8:00 PM

$CNTX very weak for over a month now in a strong biotech trend….. something seems not right? Cash problem?

0 · Reply

SpencerF Apr. 16 at 6:56 PM

$CNTX looks like we’re losing her

0 · Reply

Doom_Gloom_AR Apr. 13 at 3:34 PM

$CNTX maybe they are pipe shopping that would be miserable and a reason for the slide.

1 · Reply

stck957 Apr. 10 at 10:58 PM

$CNTX 🥲

0 · Reply

notreload_ai Apr. 2 at 2:11 PM

$CNTX CTIM-76 wins FDA Fast Track Designation for platinum-resistant ovarian cancer. Phase 1a trial ongoing with interim data expected in June 2026. https://notreload.xyz/xy/ctim-76-receives-fda-fast-track-for-ovarian-cancer/

0 · Reply

LabPsycho Apr. 2 at 2:10 PM

$CNTX People should be amazed by the prescient post below....

0 · Reply

StockConsultant Apr. 2 at 11:36 AM

$CNTX Context Therapeutics stock watch, nice trend with a pullback to 2.59 support area and bullish indicators

0 · Reply

hugoraciel Mar. 31 at 1:01 AM

$CNTX Analyst coverage is mixed — one Strong Buy, seven Buy and one Sell — yielding a MarketBeat average rating of "Moderate Buy" and an average price target of $6.60, with select firms (Piper Sandler, Guggenheim) raising targets into the $5–$7 range. So one fkn guys says SELLS and people panic? There 8 others that are saying to BUY!!!!

0 · Reply

Okaldirimj Mar. 31 at 1:00 AM

$CNTX

0 · Reply

hugoraciel Mar. 31 at 12:59 AM

$CNTX did i fkn miss something today for the 11% fkn nose dive?

0 · Reply

elmono Mar. 30 at 8:53 PM

$CNTX I’ll be waiting a bit longer…new target 1.5 if we lose 2.3…..

1 · Reply

Market Cap	219.59M
Revenue (ttm)	0.00
Net Income (ttm)	-36.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	447,808
Avg Vol	902,192
Day's Range	N/A - N/A
Shares Out	91.88M
Stochastic %K	90%
Beta	1.57
Analysts	Strong Sell
Price Target	$6.00